JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

Posted on by

SHANGHAI, March 8, 2023 /PRNewswire/ — JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of Carteyva® (relmacabtagene…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.